Expansion of CD133+ colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery

被引:111
作者
Fang, D. D. [1 ]
Kim, Y. J. [1 ]
Lee, C. N. [1 ]
Aggarwal, S. [1 ]
McKinnon, K. [1 ]
Mesmer, D. [1 ]
Norton, J. [1 ]
Birse, C. E. [1 ]
He, T. [1 ]
Ruben, S. M. [1 ]
Moore, P. A. [1 ]
机构
[1] Celera Inc, Dept Prot Therapeut, Rockville, MD 20850 USA
关键词
CSC; CD133; colon cancer; drug target; drug resistance; mass spectrometry; TUMOR-INITIATING CELLS; ACUTE MYELOID-LEUKEMIA; PANCREATIC-CANCER; BRAIN-TUMORS; CADHERIN EXPRESSION; COLORECTAL-CANCER; PROGENITOR CELLS; OVARIAN-CANCER; IDENTIFICATION; POPULATION;
D O I
10.1038/sj.bjc.6605610
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Despite earlier studies demonstrating in vitro propagation of solid tumour cancer stem cells (CSCs) as non-adherent tumour spheres, it remains controversial as to whether CSCs can be maintained in vitro. Additional validation of the CSC properties of tumour spheres would support their use as CSC models and provide an opportunity to discover additional CSC cell surface markers to aid in CSC detection and potential elimination. METHODS: Primary tumour cells isolated from 13 surgically resected colon tumour specimens were propagated using serum-free CSC-selective conditions. The CSC properties of long-term cultured tumour spheres were established and mass spectrometry-based proteomics performed. RESULTS: Freshly isolated CD133(+) colorectal cancer cells gave rise to long-term tumour sphere (or spheroids) cultures maintaining CD133 expression. These spheroid cells were able to self-renew and differentiate into adherent epithelial lineages and recapitulate the phenotype of the original tumour. Relative to their differentiated progeny, tumour spheroid cells were more resistant to the chemotherapeutic irinotecan. Finally, CD44, CD166, CD29, CEACAM5, cadherin 17, and biglycan were identified by mass spectrometry to be enriched in CD133(+) tumour spheroid cells. CONCLUSION: Our data suggest that ex vivo-expanded colon CSCs isolated from clinical specimens can be maintained in culture enabling the identification of CSC cell surface-associated proteins. British Journal of Cancer (2010) 102, 1265-1275. doi: 10.1038/sj.bjc.6605610 www.bjcancer.com Published online 23 March 2010 (C) 2010 Cancer Research UK
引用
收藏
页码:1265 / 1275
页数:11
相关论文
共 50 条
  • [41] The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer
    Horst, David
    Scheel, Silvio K.
    Liebmann, Sibylle
    Neumann, Jens
    Maatz, Susanne
    Kirchner, Thomas
    Jung, Andreas
    JOURNAL OF PATHOLOGY, 2009, 219 (04) : 427 - 434
  • [42] Role of CD133/NRF2 Axis in the Development of Colon Cancer Stem Cell-Like Properties
    Park, Jimin
    Kim, Seung Ki
    Hallis, Steffanus Pranoto
    Choi, Bo-Hyun
    Kwak, Mi-Kyoung
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [43] Proliferation Characteristics of CD133+Cell Population in Colorectal Cancer
    Yu, Dongdong
    Zhang, Yonghong
    Zou, You
    Qin, Jichao
    Li, Xiaolan
    Xiao, Hui
    Tao, Deding
    Hu, Junbo
    Gong, Jianping
    JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES, 2010, 30 (06) : 751 - 756
  • [44] Direct reprogramming of stem cell properties in colon cancer cells by CD44
    Su, Ying-Jhen
    Lai, Hsin-Mei
    Chang, Yi-Wen
    Chen, Guan-Ying
    Lee, Jia-Lin
    EMBO JOURNAL, 2011, 30 (15) : 3186 - 3199
  • [45] CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer
    Cui, Fei
    Wang, Jian
    Chen, Duan
    Chen, Yi-Jiang
    ONCOLOGY REPORTS, 2011, 25 (03) : 701 - 708
  • [46] Characterization of colon cancer cells: a functional approach characterizing CD133 as a potential stem cell marker
    Meike Schneider
    Johannes Huber
    Boris Hadaschik
    Gabrielle M Siegers
    Heinz-Herbert Fiebig
    Julia Schüler
    BMC Cancer, 12
  • [47] Unravelling cancer stem cell potential
    Beck, Benjamin
    Blanpain, Cedric
    NATURE REVIEWS CANCER, 2013, 13 (10) : 727 - 738
  • [48] Targeted Inhibition of CD133+ Cells in Oral Cancer Cell Lines
    Damek-Poprawa, M.
    Volgina, A.
    Korostoff, J.
    Sollecito, T. P.
    Brose, M. S.
    O'Malley, B. W., Jr.
    Akintoye, S. O.
    DiRienzo, J. M.
    JOURNAL OF DENTAL RESEARCH, 2011, 90 (05) : 638 - 645
  • [49] CD133 as a target for colon cancer
    Catalano, Veronica
    Di Franco, Simone
    Iovino, Flora
    Dieli, Francesco
    Stassi, Giorgio
    Todaro, Matilde
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 (03) : 259 - 267
  • [50] Isolation of Stem-Like Cancer Cells in Primary Endometrial Cancer Using Cell Surface Markers CD133 and CXCR4
    Sun, Yi
    Yoshida, Toshiko
    Okabe, Motonori
    Zhou, Kaixuan
    Wang, Fang
    Soko, Chika
    Saito, Sigeru
    Nikaido, Toshio
    TRANSLATIONAL ONCOLOGY, 2017, 10 (06): : 976 - 987